Nov
08
Removing One Inflammatory Signal Added 25 Percent to Mouse Lifespan, Starting in Old Age
0 Comments
Old mice given an antibody against a single cytokine, starting at an age equivalent to a human in their fifties, lived 22 to 25 percent longer. Two years on, the result has held up and spread into new tissues. This is what it is, and what it is not.
The short version
Interleukin-11 is a signalling protein in the IL-6 family. It rises across cell types and tissues as an animal ages, and when it does it drives an ERK–AMPK–mTORC1 axis in the wrong direction: growth and fibrosis signals up, maintenance signals down.
Anissa Widjaja and colleagues, publishing in Nature in 2024, did the two experiments that matter. Deleting the gene extended lifespan by 24.9 percent on average across both sexes. More usefully, giving an anti-IL-11 antibody to mice that were already 75 weeks old, which is late middle age for a mouse, extended median lifespan by 22.5 percent in males and 25 percent in females, while improving metabolism and muscle function and lowering frailty.
Starting late and still getting that is the part worth dwelling on. Most interventions that extend mouse lifespan are begun early. This one was begun in animals that had already done most of their aging.
Since then the picture has widened. A 2026 Nature Aging paper found IL-11 is elevated in aging ovaries in mice, rats and humans, where it stiffens the ovarian matrix, and that blocking its receptor preserved ovarian function. Another 2026 study showed neutralising antibodies relieved pulmonary fibrosis in aged mice. And a survey of 10,297 human samples found the methylation marks controlling IL-11 and its receptor change with age along an inverted U, rising then falling rather than drifting one way.
What to do with that: nothing you can buy. That is the honest answer and the rest of this article explains why, because the alternative is watching this result get attached to whatever is already on the shelf. No supplement has been shown to lower IL-11 in a human being. If you want to act on the biology rather than the headline, the reachable part is the axis IL-11 drives — ERK, AMPK and mTORC1 — and that axis is the same one fasting, exercise and a short list of plant compounds push in the opposite direction. That is an indirect route to a related place, not a substitute, and anyone telling you otherwise is selling something.
What IL-11 does
Cytokines are the messages cells send each other. IL-11 belongs to the IL-6 family and signals through the shared gp130 receptor module, which is why it has long been studied in inflammation and fibrosis rather than in aging.
The 2024 work showed that its age-related rise is not incidental. IL-11 regulates an axis of three controls that longevity research already cared about individually:
- ERK, a growth and proliferation signal
- AMPK, the low-fuel sensor that switches on maintenance and autophagy
- mTORC1, the growth switch whose suppression is the most reproducible lifespan intervention in mammals
IL-11 pushes all three the way you would not want them pushed. Remove it and they settle back. That is why one cytokine can produce an effect this large: it is not acting alone, it is sitting upstream of three things that each matter.
There is a general lesson in that which goes beyond IL-11. The interventions that produce big numbers tend to be the ones that reach a node with several outputs. Pressing on a single downstream effector rarely does much, which is the argument we make about multi-target formulations seen from the top of the tree rather than the bottom.
What the 2024 study actually did
Three experiments, in increasing order of relevance to a person.
Genetic deletion. Mice lacking Il11 or Il11ra1 were protected from metabolic decline, multi-morbidity and frailty in old age. Lifespan rose 24.9 percent on average across both sexes.
Late-life antibody. Anti-IL-11 given to 75-week-old mice for 25 weeks improved metabolism and muscle function and reduced aging biomarkers and frailty in both sexes.
Late-life lifespan. Treatment from 75 weeks until death extended median lifespan by 22.5 percent in males and 25 percent in females (Widjaja et al., 2024).
The authors noted that anti-IL-11 therapy was already in early clinical trials for fibrotic lung disease, which gives the field a route to human data without starting from zero.
What 2026 added
Ovarian aging. Wu and colleagues used atomic force microscopy to show that human ovarian matrix stiffness rises with age and in premature ovarian insufficiency, PCOS and endometriosis. Combining proteomics of human ovarian tissue with transcriptomics of human ovarian fibroblasts, they found IL-11 — elevated in aging ovaries of mice, rats and humans — activates fibroblasts to lay down extracellular matrix and stiffen the tissue. Deleting Il11ra1 in mice reduced the stiffening and the loss of ovarian function across all three conditions (Wu et al., 2026).
That is a mechanism for tissue aging that is physical rather than chemical, and it is the first time the IL-11 story has been tied to a measurable material property of human tissue.
Aging lung fibrosis. Miao and colleagues combined two neutralising antibodies against different IL-11 epitopes and relieved pulmonary fibrosis in aged mice, working through a TGF-β/NOX4/IL-11 loop (2026).
Human epigenetics. Shimura and colleagues analysed methylation at IL11 and IL11RA across 10,297 samples with a mean age of 53.9 years. Most sites in the promoter-proximal and 3′ regions followed a significant inverted U with age (2026). The epigenetic control of this pathway is not a straight line, which matters for anyone assuming a single direction of change across a lifetime.
Is there anything natural that touches it
Very little, and we are going to be precise about how little, because this is where coverage of IL-11 usually goes wrong.
The one direct result we can find involves rhoifolin, a citrus flavonoid. In a 2026 study, IL-11 was shown to drive macrophages toward an inflammatory M1 state, which then pushed fibroblasts into senescence through IL-1β and IL-6. Rhoifolin inhibited that IL-11-induced polarisation and reduced the downstream fibroblast senescence (Liao et al., 2026).
Now the caveats, all of which matter. The compound was delivered through hydrogel microneedles loaded with macrophage-membrane-coated nanoparticles, in a diabetic wound healing model. It was engineered that way precisely because getting a flavonoid to the right cells at a useful concentration is the hard part. The study tells us the IL-11 pathway is responsive to a small molecule. It does not tell us that swallowing a citrus flavonoid lowers IL-11 signalling anywhere in a person.
Beyond that, the cupboard is bare. Searching the literature for IL-11 alongside the usual candidates returns a handful of papers, none of which measured IL-11 as an endpoint in a human. Omega-3 fatty acids have been shown to inhibit IL-11/STAT3 signalling in liver cells under acetaminophen stress, which is a long way from an aging claim.
So what is a person supposed to do with this
Treat it as a map rather than a menu.
IL-11 matters because of what it controls, and what it controls is reachable by other means. AMPK rises with exercise and with fasting. mTORC1 falls with the same inputs. Compounds with real evidence against those nodes exist and we have written about several of them, including the four that a machine learning screen selected for hitting AMPK, mTORC1, SIRT1 and Nrf2 together.
What that does not do is remove the signal. An animal with no IL-11 is in a different state from an animal whose AMPK has been nudged upward, and the 25 percent number belongs to the first case, not the second. We would rather leave that gap visible than paper over it with a product.
Where this leads
Anti-IL-11 antibodies are in clinical development for fibrotic disease. If those trials report aging-adjacent outcomes in older participants, this becomes the most interesting translational story in the field. Watch for IL-11 as a measured biomarker in human trials, which is the step that has to come before anyone can claim to lower it.
Our research database holds the rest of our work on inflammation and aging, and we will update this piece when there is human data worth reporting rather than before.
Limitations
Every lifespan result here is in mice, no compound available to a consumer has been shown to lower IL-11 or its signalling in a person, and the one natural compound with direct pathway data was delivered by engineered microneedles in a wound model rather than taken by mouth.
Citations
[1] Widjaja AA, Lim WW, Viswanathan S, Chothani S, Corden B, Dasan CM, et al. Inhibition of IL-11 signalling extends mammalian healthspan and lifespan. Nature. 2024;632(8023):157-165. doi:10.1038/s41586-024-07701-9. PMID 39020175
[2] Wu M, Zhu Q, Xiong J, Tang W, et al. Modulating IL-11-dependent matrix stiffness to delay ovarian aging. Nat Aging. 2026. PMID 42393307
[3] Miao Y, Hu YY, Xu L, Meng LX, et al. IL-11 neutralizing antibodies alleviate pulmonary fibrosis in aging mice by inhibiting TGF-β/NOX4/IL-11 signaling. Biochem Pharmacol. 2026. PMID 42364821
[4] Shimura A, Dwaraka VB, Yamanishi K, Seki T. Non-linear age-related change in human interleukin-11 and the receptor subunit alpha DNA methylation. Biochem Biophys Rep. 2026. PMID 41909151
[5] Liao J, Gan L, Lu L, Ouyang L, et al. PLL-g-HPA hydrogel microneedles loaded with rhoifolin target macrophages to alleviate fibroblast senescence for diabetic wound healing. Adv Healthc Mater. 2026. PMID 42745668
These statements have not been evaluated by the Food and Drug Administration. MDS Labs does not sell any product intended to affect IL-11. Nothing here is intended to diagnose, treat, cure or prevent any disease.
Categories:
Longevity in the News
